LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

Home・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

583.14 -0.3

Buy Sell

Overview

Share price change

24h

Current

Min

570.81

Max

592.54

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	-1.99% downside

Market Stats
By TradingEconomics
Market Cap	4B 13B
Previous open	583.44
Previous close	583.14

News Sentiment

By Acuity

23%

77%

49 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Dec 2025, 23:21 UTC

Earnings

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 Dec 2025, 23:14 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 Dec 2025, 22:01 UTC

Major Market Movers

Costco Wholesale Reports Higher Monthly Sales

3 Dec 2025, 21:38 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 Dec 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 Dec 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 Dec 2025, 23:10 UTC

Earnings

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 Dec 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 Dec 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 Dec 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 Dec 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 Dec 2025, 22:20 UTC

Earnings

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 Dec 2025, 22:19 UTC

Earnings

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 Dec 2025, 22:17 UTC

Earnings

Salesforce Working to Add Voice to Agentforce, CEO Says

3 Dec 2025, 22:16 UTC

Earnings

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 Dec 2025, 22:15 UTC

Earnings

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 Dec 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 Dec 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 Dec 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Dec 2025, 21:49 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:23 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 Dec 2025, 21:19 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:06 UTC

Earnings

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 Dec 2025, 21:03 UTC

Earnings

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-1.99% downside

12 Months Forecast

Average 561.73 USD -1.99%

High 650 USD

Low 445 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

49 / 374 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.